Literature DB >> 17137471

Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: correlation between the platelet defect and the alpha-granule content in the patient and four relatives.

E De Candia1, A Pecci, G Ciabattoni, R De Cristofaro, S Rutella, Z Yao-Wu, I Lazzareschi, R Landolfi, S Coughlin, C L Balduini.   

Abstract

BACKGROUND: We report a novel case of gray platelet syndrome (GPS). A 14-year-old boy had bleeding diathesis, mild thrombocytopenia, giant platelets with severe defect of alpha-granule secretory proteins, myelofibrosis and splenomegaly. METHODS AND
RESULTS: Platelet function studies showed a marked reduction of aggregation and Ca(2+) mobilization by thrombin, protease-activated receptor 1 (PAR1)-activating peptide (AP) and PAR4-AP, PAR1 expression at 55% of normal levels, and a more than two hundred fold reduction of in vitro whole-blood thromboxane B(2) (TXB(2)) production. Sequencing of coding regions of the PAR1 gene failed to show abnormalities. This patient was initially classified as a sporadic case of GPS, as electron microscopy failed to identify giant platelets and/or alpha-granule deficiency in his relatives. However, further studies on the father and three other relatives showed a relative lack of platelet alpha-granule proteins by immunofluorescence microscopy, a defective platelet response to PAR4-AP, and severely reduced in vitro whole-blood TXB(2) production. On this basis, we suggest that in this family, GPS was transmitted in a dominant fashion with highly variable penetrance.
CONCLUSIONS: Our study suggests that current diagnostic criteria fail to identify some patients with a mild GPS phenotype and that such patients might be identified by the methods cited above. It also better characterizes the pathogenesis of defective platelet responses to thrombin, and raises interesting questions on the correlation between abnormal PAR function and the lack of alpha-granule content in GPS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17137471     DOI: 10.1111/j.1538-7836.2007.02329.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  4 in total

1.  Phenotypic heterogeneity in the Gray platelet syndrome extends to the expression of TREM family member, TLT-1.

Authors:  Alan T Nurden; Paquita Nurden; Emilsé Bermejo; Robert Combrié; Daniel W McVicar; A Valance Washington
Journal:  Thromb Haemost       Date:  2008-07       Impact factor: 5.249

2.  Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and α-granule deficiency.

Authors:  Roberta Bottega; Alessandro Pecci; Erica De Candia; Nuria Pujol-Moix; Paula G Heller; Patrizia Noris; Daniela De Rocco; Gian Marco Podda; Ana C Glembotsky; Marco Cattaneo; Carlo L Balduini; Anna Savoia
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

3.  Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients.

Authors:  Christian A Di Buduo; Maria Adele Alberelli; Ana C Glembostky; Gianmarco Podda; Paola R Lev; Marco Cattaneo; Raffaele Landolfi; Paula G Heller; Alessandra Balduini; Erica De Candia
Journal:  Sci Rep       Date:  2016-03-18       Impact factor: 4.379

4.  Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in Mice.

Authors:  Kärt Tomberg; Rami Khoriaty; Randal J Westrick; Heather E Fairfield; Laura G Reinholdt; Gary L Brodsky; Pavel Davizon-Castillo; David Ginsburg; Jorge Di Paola
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.